Phase 3Active, not recruitingINTERVENTIONAL
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
ClinicalTrials.gov · NCT06884293 · Registry updated: 2026-05-12
- Condition / research focus
- Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2025-05-09. Completion: 2027-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- IBI362 (drug)
- semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Beijing Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported